North America Monoclonal Antibodies Market

North America Monoclonal Antibodies Market Size (2023 to 2028)

The size of the Monoclonal Antibodies Market in North America was worth USD 15.92 Billion in 2023 and is estimated to grow at a CAGR of 6.24%, to reach USD 21.55 Billion by 2028.

The increasing prevalence of chronic diseases, particularly heart-related disorders and cancer is a significant driving factor for market growth in the North American region. Cancer is a major cause of mortality in this area. Approximately 1.9 million new cancer cases were recorded in the United States alone. Factors such as changes in lifestyle habits, hormonal fluctuations, heightened exposure to polluted air, and genetic predispositions contribute to the rising cancer cases among the population. Researchers are actively focusing on innovating new treatments to reduce this mortality rate. Monoclonal antibody therapy stands out as one of the advanced treatments for cancer, wherein laboratory-produced proteins act similarly to natural antibodies present in the human body. These monoclonal antibodies are effectively employed in targeted cancer therapy, which uses drugs and substances to precisely identify and attack specific cancer cells. This targeted therapy is often combined with chemotherapy, surgery, and radiation therapy. Antibodies, crucial immune system components, play a vital role in defending against foreign particles and facilitating their destruction.

The growing demand for biologics and heightened awareness about monoclonal antibodies' benefits contribute to the growth of the North American market. Biologics is a class of drugs produced using living systems, encompassing monoclonal antibodies among their key examples. These biologics are extensively utilized in treating various diseases, including autoimmune conditions like rheumatoid arthritis, certain cancers, viral infections and gastrointestinal disorders.

The growing number of applications of monoclonal antibodies further propel the growth of the North American market. Researchers are focused on developing monoclonal antibody therapy to address the rising number of heart-related issues. Recent developments include anti-PCSK9 monoclonal antibodies that improve LDL cholesterol levels, reducing the risk of hypercholesterolemia and associated conditions like myocardial infarction, ischemia, ischemic stroke, and peripheral artery disease. Efforts are being made to develop therapies for various conditions, such as infections, eye conditions, migraines and organ transplant rejection. The growing investments from public and private organizations, government support and continuous advancements in therapy innovations support the monoclonal antibodies market growth in North America.

The high costs associated with monoclonal antibody preparation in laboratories majorly hamper the North American market growth. Factors such as the shortage of skilled professionals, limited awareness about the treatment, inadequate reimbursement policies in certain areas and stringent regulations, further hinder the market's progress during the forecast period. Additionally, monoclonal antibodies present challenges, including potential adverse effects such as high blood pressure, heart attacks, and lung problems.

This research report on the North American Monoclonal Antibodies Market has been segmented & sub-segmented into the following categories:

By Source:

• Murine
• Chimeric
• Humanized
• Human

By Indication:

• Cancer
  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Others)

By End-User: 

• Hospitals/Clinics
• Research Institute
• Diagnostic Laboratories

By Application: 

• Medical
• Experimental
• Western Blot
  • ELISA
  • Radioimmune Assays
  • Immunofluorescence
  • Others

By Country: 

• The U.S.
• Canada
• Rest of North America

North America held the major share of the global market in 2022 and the domination of the North American region in the worldwide market is expected to continue throughout the forecast period owing to the advancements in the healthcare sector and growing healthcare expenditure. The U.S. is estimated to hold the major share of the North American market during the forecast period owing to the increasing number of mergers and acquisitions, a growing geriatric population, a strong presence of key players, and supportive government initiatives. The growing demand for monoclonal antibody therapies amid the COVID-19 pandemic and the expansion of laboratory facilities in the U.S. further aids the U.S. market growth. FDA approvals for monoclonal antibody therapies in 2021 have boosted immunity and aided the fight against the virus. Canada is expected to occupy a notable share of North American in the coming years owing to the widespread adoption of monoclonal antibody therapies in various hospitals, supported by government measures and approvals through clinical trials.

KEY MARKET PARTICIPANTS:

Some of the major companies dominating the market by their products include GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., and Biogen Inc.